![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SREK1 |
Gene summary for SREK1 |
![]() |
Gene information | Species | Human | Gene symbol | SREK1 | Gene ID | 140890 |
Gene name | splicing regulatory glutamic acid and lysine rich protein 1 | |
Gene Alias | SFRS12 | |
Cytomap | 5q12.3 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q8WXA9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
140890 | SREK1 | LN46 | Human | Oral cavity | OSCC | 5.49e-06 | 5.57e-01 | 0.1666 |
140890 | SREK1 | LP15 | Human | Oral cavity | LP | 1.28e-02 | 9.48e-01 | 0.2174 |
140890 | SREK1 | EOLP-1 | Human | Oral cavity | EOLP | 1.21e-03 | 1.42e-01 | -0.0202 |
140890 | SREK1 | NEOLP-3 | Human | Oral cavity | NEOLP | 1.22e-02 | 1.84e-01 | -0.0191 |
140890 | SREK1 | SYSMH1 | Human | Oral cavity | OSCC | 8.70e-09 | 2.57e-01 | 0.1127 |
140890 | SREK1 | SYSMH2 | Human | Oral cavity | OSCC | 4.99e-32 | 8.67e-01 | 0.2326 |
140890 | SREK1 | SYSMH3 | Human | Oral cavity | OSCC | 7.95e-34 | 9.24e-01 | 0.2442 |
140890 | SREK1 | SYSMH4 | Human | Oral cavity | OSCC | 2.59e-03 | 1.08e-01 | 0.1226 |
140890 | SREK1 | SYSMH5 | Human | Oral cavity | OSCC | 1.33e-05 | 2.37e-01 | 0.0647 |
140890 | SREK1 | SYSMH6 | Human | Oral cavity | OSCC | 6.03e-08 | 3.42e-01 | 0.1275 |
140890 | SREK1 | HTA12-26-1 | Human | Pancreas | PDAC | 7.86e-13 | 7.52e-01 | 0.3728 |
140890 | SREK1 | HTA12-29-1 | Human | Pancreas | PDAC | 9.52e-26 | 6.14e-01 | 0.3722 |
140890 | SREK1 | GSM5252137_BPH556PrGA2_Fcol | Human | Prostate | BPH | 8.98e-06 | 4.74e-01 | -0.23 |
140890 | SREK1 | 047563_1562-all-cells | Human | Prostate | BPH | 9.20e-08 | -1.31e-01 | 0.0791 |
140890 | SREK1 | Dong_P1 | Human | Prostate | Tumor | 2.20e-15 | -6.58e-02 | 0.035 |
140890 | SREK1 | Dong_P3 | Human | Prostate | Tumor | 1.19e-10 | 1.82e-02 | 0.0278 |
140890 | SREK1 | Dong_P4 | Human | Prostate | Tumor | 1.13e-03 | 7.93e-02 | 0.0292 |
140890 | SREK1 | Dong_P5 | Human | Prostate | Tumor | 3.78e-21 | -1.21e-01 | 0.053 |
140890 | SREK1 | GSM5353221_PA_PB2A_Pool_1_3_S25_L001 | Human | Prostate | Tumor | 2.82e-02 | 3.64e-01 | 0.1633 |
140890 | SREK1 | GSM5353224_PA_PR5186_Pool_1_2_3_S27_L001 | Human | Prostate | Tumor | 6.85e-09 | 6.32e-01 | 0.1621 |
Page: 1 2 3 4 5 6 7 8 9 10 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0008380 | Colorectum | AD | RNA splicing | 169/3918 | 434/18723 | 3.59e-18 | 2.04e-15 | 169 |
GO:00083801 | Colorectum | SER | RNA splicing | 123/2897 | 434/18723 | 3.84e-12 | 8.41e-10 | 123 |
GO:00083802 | Colorectum | MSS | RNA splicing | 159/3467 | 434/18723 | 1.75e-19 | 1.22e-16 | 159 |
GO:00083804 | Colorectum | FAP | RNA splicing | 108/2622 | 434/18723 | 7.90e-10 | 1.86e-07 | 108 |
GO:00083805 | Colorectum | CRC | RNA splicing | 90/2078 | 434/18723 | 2.80e-09 | 7.97e-07 | 90 |
GO:000838016 | Endometrium | AEH | RNA splicing | 111/2100 | 434/18723 | 2.42e-17 | 1.12e-14 | 111 |
GO:000838017 | Endometrium | EEC | RNA splicing | 111/2168 | 434/18723 | 2.45e-16 | 1.13e-13 | 111 |
GO:000838026 | Esophagus | HGIN | RNA splicing | 160/2587 | 434/18723 | 3.74e-34 | 1.12e-30 | 160 |
GO:0008380111 | Esophagus | ESCC | RNA splicing | 336/8552 | 434/18723 | 1.74e-42 | 3.67e-39 | 336 |
GO:00083807 | Liver | NAFLD | RNA splicing | 70/1882 | 434/18723 | 4.62e-05 | 1.10e-03 | 70 |
GO:000838012 | Liver | Cirrhotic | RNA splicing | 229/4634 | 434/18723 | 9.13e-37 | 2.86e-33 | 229 |
GO:000838022 | Liver | HCC | RNA splicing | 313/7958 | 434/18723 | 1.36e-36 | 1.73e-33 | 313 |
GO:000838020 | Oral cavity | OSCC | RNA splicing | 308/7305 | 434/18723 | 2.43e-42 | 7.70e-39 | 308 |
GO:0008380110 | Oral cavity | LP | RNA splicing | 237/4623 | 434/18723 | 1.82e-41 | 3.79e-38 | 237 |
GO:000838025 | Oral cavity | EOLP | RNA splicing | 115/2218 | 434/18723 | 2.24e-17 | 3.04e-14 | 115 |
GO:000838033 | Oral cavity | NEOLP | RNA splicing | 110/2005 | 434/18723 | 2.29e-18 | 2.72e-15 | 110 |
GO:000838018 | Prostate | BPH | RNA splicing | 147/3107 | 434/18723 | 5.17e-19 | 2.29e-16 | 147 |
GO:000838019 | Prostate | Tumor | RNA splicing | 153/3246 | 434/18723 | 9.15e-20 | 5.79e-17 | 153 |
GO:000838027 | Skin | AK | RNA splicing | 111/1910 | 434/18723 | 1.85e-20 | 5.49e-17 | 111 |
GO:0008380112 | Skin | cSCC | RNA splicing | 263/4864 | 434/18723 | 2.45e-53 | 5.13e-50 | 263 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SREK1 | SNV | Missense_Mutation | novel | c.1718N>T | p.Ser573Leu | p.S573L | Q8WXA9 | protein_coding | deleterious_low_confidence(0) | benign(0.009) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
SREK1 | SNV | Missense_Mutation | novel | c.39C>G | p.Phe13Leu | p.F13L | Q8WXA9 | protein_coding | tolerated_low_confidence(0.1) | benign(0.012) | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
SREK1 | SNV | Missense_Mutation | rs774604410 | c.920N>A | p.Arg307Gln | p.R307Q | Q8WXA9 | protein_coding | deleterious(0.03) | benign(0.007) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SREK1 | SNV | Missense_Mutation | c.869C>T | p.Ser290Leu | p.S290L | Q8WXA9 | protein_coding | deleterious(0) | possibly_damaging(0.778) | TCGA-C8-A275-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
SREK1 | SNV | Missense_Mutation | c.1022C>T | p.Ser341Leu | p.S341L | Q8WXA9 | protein_coding | deleterious(0.02) | probably_damaging(0.985) | TCGA-DG-A2KK-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD | |
SREK1 | SNV | Missense_Mutation | c.136G>C | p.Glu46Gln | p.E46Q | Q8WXA9 | protein_coding | deleterious(0.02) | probably_damaging(0.95) | TCGA-EK-A2R8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
SREK1 | SNV | Missense_Mutation | c.592N>A | p.Gln198Lys | p.Q198K | Q8WXA9 | protein_coding | deleterious(0.01) | probably_damaging(0.954) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
SREK1 | SNV | Missense_Mutation | rs767832773 | c.1298N>C | p.Arg433Thr | p.R433T | Q8WXA9 | protein_coding | tolerated(0.16) | benign(0.056) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
SREK1 | SNV | Missense_Mutation | c.1649G>A | p.Arg550His | p.R550H | Q8WXA9 | protein_coding | tolerated_low_confidence(0.13) | benign(0.003) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
SREK1 | SNV | Missense_Mutation | c.389C>T | p.Pro130Leu | p.P130L | Q8WXA9 | protein_coding | deleterious(0) | possibly_damaging(0.569) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |